Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02257138 | Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02397720 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 |
| clinicaltrials |
| NCT03831776 | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis(BosuPeg) | completed | Phase 2 | 212 | St. Olavs HospitalOTHER | 4 | Jun 8, 2025 | clinicaltrials |
| NCT01860456 | TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study(TIKlet) | completed | — | 412 | University of PisaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05941585 | Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia | completed | N/A | 60 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01184898 | Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) | completed | N/A | 36 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03844997 | Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 35 | Sudipto Mukherjee, MD, PhD, MPHOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02937662 | Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML | completed | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06993883 | Use of Venetoclax , AML , Sohag , Egypt(AML) | completed | — | 43 | Sohag UniversityOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT02577406 | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation(IDHENTIFY) | completed | Phase 3 | 319 | CelgeneINDUSTRY | 18 | May 18, 2025 | clinicaltrials |
| NCT03066648 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | completed | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 8 | May 18, 2025 | clinicaltrials |
| NCT01350245 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | completed | Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03149055 | Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) | completed | Phase 2 | 99 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06697899 | TGRX-678 Phase I Oral Pharmacokinetic Study | completed | Phase 1 | 76 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT03063944 | STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy | completed | Phase 1 | 37 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04081259 | LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | completed | Phase 1 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT00898755 | Collecting and Storing Tissue From Young Patients With Cancer | completed | — | 213 | Children's Oncology GroupNETWORK | 2 | May 2, 2025 | clinicaltrials |
| NCT05053100 | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | completed | — | 100 | Mayo ClinicOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05458258 | Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia | completed | — | 239 | University of ChicagoOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01822015 | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Early Phase 1 | 55 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03008187 | MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia(Diamond-01) | completed | Phase 1 / Phase 2 | 73 | Menarini GroupINDUSTRY | 4 | Apr 29, 2025 | clinicaltrials |
| NCT04628338 | IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | completed | Early Phase 1 | 8 | Sawa Ito, MDOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04694820 | A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia | completed | N/A | 30 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06945146 | Genomics Study in CML Patients With Ponatinib Treatment(CAP) | completed | — | 65 | Dong-Wook KimOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02566304 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 35 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04487106 | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT01699217 | Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase(CML0912) | completed | — | 129 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04795427 | Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | completed | Phase 2 | 84 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02658487 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia(VITAL) | completed | Phase 2 | 42 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03813147 | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2025 | clinicaltrials |
| NCT01892371 | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03755414 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | completed | Phase 1 | 55 | Washington University School of MedicineOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT00588991 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06904859 | The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia | completed | Early Phase 1 | 50 | Shenzhen University General HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT02852486 | Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response(EDI-PIO) | completed | Phase 2 | 31 | University of Campinas, BrazilOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT04277442 | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | completed | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2025 | clinicaltrials |
| NCT05166135 | Latin American Real-world Study in Acute Leukemia(LOYAL) | completed | — | 589 | PfizerINDUSTRY | 4 | Mar 25, 2025 | clinicaltrials |
| NCT03280030 | A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | completed | Phase 2 | 67 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2025 | clinicaltrials |
| NCT02193958 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 55 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT01050036 | Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia | completed | N/A | 20 | Asan Medical CenterOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT01804985 | De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia(DESTINY) | completed | Phase 2 | 174 | University of LiverpoolOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06865352 | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 15 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT02834390 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 | 7 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06488456 | Psychometric Properties of the Therapy-Related Symptom Checklist-Children | completed | — | 300 | Ege UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2025source: clinicaltrials